GLYCOPYRROLATE MSDS PDF

SAFETY DATA SHEET. PRODUCT: Glycopyrrolate Injection USP. Section 1: PRODUCT AND COMPANY INFORMATION. 54/1, Boodhihal village,. Nelamangala. Glycopyrrolate. 1-Methylpyrrolidyl alpha-phenylcyclopentaneglycolate methobromide;. Glycopyrrolate bromide; Glycopyrronium bromide. Glycopyrronium (as the bromide salt glycopyrrolate) is a synthetic anticholinergic agent In October , glycopyrrolate was approved by the FDA for use as a FDA label. Download ( KB). MSDS. Download ( KB).

Author: Tojalar Doujas
Country: Serbia
Language: English (Spanish)
Genre: Marketing
Published (Last): 21 February 2012
Pages: 294
PDF File Size: 16.17 Mb
ePub File Size: 20.66 Mb
ISBN: 945-6-92563-171-2
Downloads: 2011
Price: Free* [*Free Regsitration Required]
Uploader: Faedal

Tyrothricin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Tyrothricin.

Glycopyrronium – DrugBank

Carfentanil The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Carfentanil. Glycopyrrolate binds competitively to the muscarinic acetylcholine receptor. Glycopyrrolafe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Levorphanol.

Bethanidine The risk or severity of Tachycardia can be increased smds Bethanidine is combined with Glycopyrronium. The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Phenserine. Thiotepa The glycopyrrolaate efficacy of Glycopyrronium can be decreased when used in combination with Thiotepa.

The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Ephedrine. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Glycopyrronium. Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Glycopyrronium is combined with Topiramate.

The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Amibegron. Aprobarbital Glycopyrronium may increase the anticholinergic activities of Aprobarbital.

Drugs, their targets and the nature and number of drug targets. The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Glycopyrronium. Rivastigmine The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Rivastigmine.

Isepamicin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Isepamicin. Levonordefrin The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Levonordefrin.

  30402 BOSCH PDF

The serum concentration of Polythiazide can be increased when it is combined with Glycopyrronium. Moxonidine The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Moxonidine.

Arformoterol The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Arformoterol. The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Anisodamine. Lactulose The therapeutic efficacy of Lactulose can glyxopyrrolate decreased when used in combination with Glycopyrronium.

The glycopyrrokate or severity of Tachycardia can be increased when Glycopyrronium is combined with Mefenorex. Sennosides The therapeutic efficacy of Sennosides can be decreased when used in combination with Glycopyrronium. The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Opium.

Tiotropium The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Tiotropium. The therapeutic efficacy of Castor oil can be decreased when msfs in combination with Glycopyrronium.

Diphemanil The risk or severity of adverse effects can be increased when Diphemanil is combined with Glycopyrronium. Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Glycopyrronium. The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Buprenorphine.

The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Paraoxon. The risk or severity of Tachycardia and drowsiness can be increased when Glycopyrronium is combined with Cannabidiol. The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Ambenonium. The risk or severity of adverse effects can be increased when Mivacurium is combined with Glycopyrronium. The risk or severity of adverse effects can be increased when Mebeverine is combined with Glycopyrronium.

Glycopyrronium

The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Ketamine. The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Glycopyrronium. The risk or severity of adverse effects can be increased when Difemerine is combined with Glycopyrronium.

  CARMEN LYRA EN UNA SILLA DE RUEDAS PDF

Plazomicin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Plazomicin. The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Homatropine. The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Hydromorphone. Perindopril The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Perindopril.

Ephedra The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Ephedra. Remifentanil The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Remifentanil. Mepenzolate The risk or severity of adverse effects can be increased when Mepenzolate is combined with Vlycopyrrolate.

The risk or severity of Tachycardia can be increased when Phenylephrine is combined with Glycopyrronium. The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Memantine. The risk or severity of adverse effects can be increased when Nortriptyline is combined with Glycopyrronium. Mianserin Mianserin may increase the anticholinergic activities of Glycopyrronium.

The risk or severity of Tachycardia can be increased when Bitolterol is combined with Glycopyrronium.

Desvenlafaxine The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Desvenlafaxine. Dexetimide The risk or severity of adverse effects can be increased when Dexetimide is combined with Glycopyrronium. Sodium iodide The therapeutic efficacy of Sodium iodide can be decreased when used in combination with Glycopyrronium. The therapeutic efficacy of Aluminum sulfate can be decreased when used in combination with Glycopyrronium.

Sodium aurotiosulfate The therapeutic efficacy of Sodium aurotiosulfate can be decreased when used in combination with Glycopyrronium. CP The risk or severity of Tachycardia and drowsiness can be increased when Glycopyrronium is combined with CP